• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM 2.70% 38.0¢

IMMUTEP LIMITED - Corporate Spotlight

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No Corporate Spotlight currently available.

(20min delay)
Last
38.0¢
Change
0.010(2.70%)
Mkt cap ! $451.7M
Open High Low Value Volume
36.5¢ 38.3¢ 36.5¢ $219.2K 583.5K

Buyers (Bids)

No. Vol. Price($)
2 52027 37.0¢
 

Sellers (Offers)

Price($) Vol. No.
38.0¢ 2713 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
38.0¢
  Change
0.010 ( 2.43 %)
Open High Low Volume
37.0¢ 38.0¢ 37.0¢ 151143
Last updated 15.59pm 28/03/2024 ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.